Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Bought by Octagon Capital Advisors LP

Octagon Capital Advisors LP increased its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 99.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 18,350,000 shares of the company's stock after acquiring an additional 9,162,117 shares during the quarter. Gossamer Bio makes up approximately 2.7% of Octagon Capital Advisors LP's holdings, making the stock its 14th biggest holding. Octagon Capital Advisors LP owned approximately 8.10% of Gossamer Bio worth $16,599,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in GOSS. Graham Capital Management L.P. purchased a new position in shares of Gossamer Bio in the 4th quarter worth about $32,000. Fullcircle Wealth LLC purchased a new position in Gossamer Bio in the 4th quarter worth approximately $43,000. Bank of America Corp DE grew its stake in shares of Gossamer Bio by 107.2% during the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company's stock valued at $77,000 after acquiring an additional 43,866 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of Gossamer Bio during the 4th quarter valued at approximately $90,000. Finally, Lazard Asset Management LLC increased its holdings in Gossamer Bio by 7,992.6% in the fourth quarter. Lazard Asset Management LLC now owns 107,470 shares of the company's stock valued at $97,000 after buying an additional 106,142 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on GOSS shares. Wedbush reaffirmed an "outperform" rating and issued a $4.00 target price on shares of Gossamer Bio in a research report on Friday, March 14th. The Goldman Sachs Group decreased their price target on shares of Gossamer Bio from $8.00 to $7.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a research note on Tuesday, March 18th.

Gossamer Bio Stock Down 0.9%

NASDAQ GOSS opened at $1.10 on Tuesday. Gossamer Bio, Inc. has a one year low of $0.50 and a one year high of $1.55. The firm has a market cap of $249.94 million, a PE ratio of -3.44 and a beta of 1.82. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The stock's 50 day simple moving average is $1.06 and its 200 day simple moving average is $0.99.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). The business had revenue of $9.38 million for the quarter, compared to the consensus estimate of $7.02 million. As a group, sell-side analysts forecast that Gossamer Bio, Inc. will post -0.28 earnings per share for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.